Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval

Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval

Zongertinib induced responses in 75% of mutation carriers with non-squamous NSCLC

FDA Approves Zongertinib for HER2 TKD Mutation-Positive Nonsquamous NSCLC Based on Beamion LUNG-1 Trial

The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Approves Zongertinib for HER2 TKD Mutation-Positive Nonsquamous NSCLC Based on Beamion LUNG-1 Trial first appeared on GeneOnline News. The post FDA Approves Zongertinib for HER2 TKD Mutation-Positive Nonsquamous NSCLC Based on Beamion LUNG-1 Trial appeared first on GeneOnline News.

Zongertinib Granted Accelerated Approval in Nonsquamous NSCLC for HER2 TKD-Activating Mutations

Zongertinib gains FDA approval for treating HER2-mutated non–small cell lung cancer (NSCLC), offering hope with fewer side effects and promising response rates in patients.

Zongertinib Nabs FDA Approval in Nonsquamous HER2 TKD+ NSCLC

FDA accelerated approval was given to zongertinib for the treatment of patients with unresectable/metastatic nonsquamous NSCLC with HER2 TKD activating mutations.

FDA approves Boehringer’s pill for HER2-mutated lung cancer

The FDA granted accelerated approval to Boehringer Ingelheim’s targeted therapy zongertinib for certain lung cancer patients with HER2 mutations, giving them a potentially safer targeted therapy that also comes as a pill. The regulator ...

FDA Grants Accelerated Approval to Zongertinib in HER2 NSCLC

Zongertinib gains FDA approval for advanced NSCLC with HER2 mutations, showcasing promising efficacy and safety in clinical trials.